What Adults With Haemophilia A in Germany Prefer in Preventive Treatment
Asks adults with haemophilia A to choose between hypothetical preventive treatment options.
Plain-language title generated from the registry record
Registry title: Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany
Key facts
- Where
- Mainz, GermanySee the site
Where in Germany
- MainzMainz, GermanyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07653139
- Record updated
- 6 October 2026
- Original description
This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation processes. The study will examine how individuals with haemophilia A evaluate trade-offs between treatment effectiveness, safety, and treatment administration characteristics when choosing between prophylactic therapies. Participants will repeatedly choose between hypothetical treatment profiles that differ in clinically relevant attributes and levels.Read full original descriptionShow less
Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany
This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation processes. The study will examine how individuals with haemophilia A evaluate trade-offs between treatment effectiveness, safety, and treatment administration characteristics when choosing between prophylactic therapies. Participants will repeatedly choose between hypothetical treatment profiles that differ in clinically relevant attributes and levels.
Inclusion: Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol); Participant has the mental capacity and sufficient German language proficiency to understand the study procedures and to complete the survey; Age above or equal to 18 years at the time of signing informed consent; Validated diagnose with haemophilia A, with and without inhibitors; Resident in Germany.
Exclusion: Age below 18 years at the time of signing informed consent; No provision of informed consent in this study; Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation; Absence of a diagnosis of haemophilia A; No residence in Germany.